Sosei Heptares Receives Approval for Change of Market Listing Segment to the Tokyo Stock Exchange Prime Market
08 mars 2023 03h00 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 8 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and...
OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023.
21 févr. 2023 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) (“OKYO”, “OKYO Pharma” or the “Company”), an ophthalmology-focused bio-pharmaceutical company...
Orion Biotechnology Presenting at the 2nd GPCR-Targeted Drug Discovery Summit in Boston
16 févr. 2023 13h15 HE
|
Orion Biotechnology Canada Ltd.
Ottawa, Canada, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G...
Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2022
14 févr. 2023 01h30 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 14 February 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD)...
硕迪生物宣布完成经增发的首次公开募股包括承销商全面行使购买额外美国存托股票的选择权
07 févr. 2023 16h00 HE
|
Structure Therapeutics Inc.
旧金山和上海, Feb. 08, 2023 (GLOBE NEWSWIRE) --...
Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
07 févr. 2023 16h00 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
硕迪生物宣布经增发的首次公开募股的定价
02 févr. 2023 20h59 HE
|
Structure Therapeutics Inc.
加利福尼亚州旧金山和中国上海, Feb. 03, 2023 (GLOBE NEWSWIRE) -- 硕迪生物技术有限公司（纳斯达克股票代码：GPCR）是一家临床阶段的全球化生物制药公司，致力于口服小分子药物的创新研发以治疗代谢性和肺部疾病。今日，公司宣布其经增发的首次公开募股的定价。公司拟发行10,740,000股美国存托股票（ADS），每股ADS代表三股普通股，公开发行价格为每股ADS...
Structure Therapeutics Announces Pricing of Upsized Initial Public Offering
02 févr. 2023 19h41 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small...
Orion Biotechnology Publishes Whitepaper Highlighting the Importance and Challenges in Unlocking “Undruggable” GPCRs
02 févr. 2023 10h07 HE
|
Orion Biotechnology Canada Ltd.
Ottawa, Canada, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G...
Sosei Heptares Webinar Presentation for FY2022 Financial Results
25 janv. 2023 01h30 HE
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused...